source
- Lilly beats forecasts and raises outlook as Novartis steadies and GSK faces investor pressureLilly reported third‑quarter revenue that exceeded analysts' expectations by about 8%, driven by strong demand for its diabetes and obesity treatments Mounjaro and Zepbound. The company also lifted…
- Setara Biosciences launches with $90 million to pursue Charcot-Marie-Tooth and other rare-disease therapiesSetara Biosciences announced its formation on Friday, backed by $90 million of financing to advance a pipeline of experimental medicines. The company’s first candidate targets the genetic disorder…